The results of all prostate biopsies may be positive and suggestive of adenocarcinoma in patients with prostate-specific antigen (PSA) values higher than 100 ng/ml. We considered that the prostate cancer in patients with high PSA might be advanced disease and therefore that the treatment strategy should not be changed according to pathological reports. Thus, we assessed the role of prostate biopsy when diagnosing prostate cancer in patients with extremely high PSA levels.
INTRODUCTION
The incidence of prostate cancer has been gradually increasing in Korea. The increase in the aged population, a westernized lifestyle, the development of diagnostic tools, and national surveillance programs for early prostate cancer detection may all have contributed to the increased detection rate of prostate cancer.
Checking the serum prostate-specific antigen (PSA) level and a digital rectal examination (DRE) are the gold standards for prostate cancer screening. If repeated PSA levels exceed 4 ng/ml or prostate nodule or asymmetry are found by DRE, transrectal ultrasonography (TRUS)-guided needle biopsy is performed to pathologically confirm the diagnosis [1, 2] .
A higher PSA value is more frequently associated either with prostate cancer or with advanced disease, even though the opposite opinions have been reported in some cases (e.g., prostate cancer prediction with low PSA in the case of elderly patients with abnormal DRE and TRUS findings) [3] . More than 50% of men with a PSA value higher than 10 ng/ml have extra-prostatic disease. Twenty percent of men with a PSA higher than 20 ng/ml and 75% of those with a PSA higher than 50 ng/ml are found to have pelvic lymph node involvement [4] .
Common complications of prostate biopsy include postbiopsy infections and bleeding. Coagulopathy and immunosuppression can be problematic, and severe conditions are contraindications to prostate biopsy. After TRUS-guided needle biopsy, most infectious complications are limited to symptomatic urinary tract infection and low-grade febrile illness; however, recent studies showed that 1.4% of patients will go on to develop a febrile urinary tract infection, bacteremia, or acute prostatitis and require hospitalization for treatment with intravenous antibiotics [5] .
Bleeding is the most common complication seen after prostate biopsy, even with normal coagulation parameters. It can present as hematuria, rectal bleeding, or hematospermia. Other complications include acute urinary retention (AUR), which may require temporary catheterization, the chance of which is increased with a prior history of benign prostatic hyperplasia and older age [6, 7] .
Therefore, particularly in patients with extremely elevated serum PSA levels and old age, prostate biopsy to confirm the diagnosis of prostate cancer should be carefully considered owing to possibly fatal complications. To prove the necessity for prostate biopsy in this group, we reviewed the outcomes of TRUS-guided prostate needle biopsy in patients with elevated PSA levels. We grouped the patients according to their PSA levels and calculated the positive predictive value (PPV).
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 1,150 patients who underwent TRUS-guided prostate needle biopsy for the evaluation of prostate cancer from January 2000 to December 2010. Patients with a pre-biopsy PSA level less than 4 ng/ml were excluded from the study. We also excluded patients with acute prostatitis and acute urinary retention. In total, 1,121 patients were reviewed in this study.
All patients took antibiotic prophylaxis (either PO quinolones or third-generation cephalosporins) for 7 days, starting from the day before the biopsy. If any signs or symptoms suggesting urinary tract infection occurred, the procedure was canceled. Patients taking anticoagulation agents stopped the medication for at least 5 days before the biopsy. For most of the patients, 12-core or double sextant biopsy (i.e., right peripheral 3 core, right medial 3 core, left peripheral 3 core, and left medial 3 core) was performed. One or more cores were added if suspicious hypoechoic lesions or palpable nodules were present on ultrasound or DRE. Some patients in poor general condition underwent standard sextant biopsy or 8-core biopsy.
According to the pre-biopsy PSA level, patients were divided into 6 groups (group A, 4 to 20 ng/ml; B, 20 to 40 ng/ml; C, 40 to 60 ng/ml; D, 60 to 80 ng/ml; E, 80 to 100 ng/ml; and F, above 100 ng/ml). The patients' age, pre-biopsy PSA level, the result of biopsy (i.e., cancer cell type and the Gleason score), and clinical or pathologic TNM stage were compared. The cancer detection rate was analyzed for each group.
RESULTS
Overall, 356 (31.8%) of the 1,121 patients had prostate carcinoma. The mean age of the patients with reported prostate cancer at biopsy was 65.8 years (range, 34 to 88 years) and that of the patients with a negative biopsy result was 70.1 years (range, 38 to 91 years). The mean PSA level of the patients with a positive biopsy result was 16.12 ng/ml (range, 4.82 to 7,176 ng/ml). The mean PSA level of patients with a negative result was 10.39 ng/ml (range, 4.12 to 85.5 ng/ml). The detection rate was gradually increased as the pre-biopsy PSA level increased. For example, only 21.8% of group A (i.e., PSA 4 to 20 ng/ml) had prostate cancer, whereas all 65 patients of group F (PSA ＞100 ng/ml) had cancer (positive predictive value=100.0%), as presented in Fig. 1 .
All 356 patients had prostate adenocarcinoma. Among them, 107 had high-grade cancer (Gleason score ≥8). The percentage of high-grade cancer was 30% in total, which increased to 71% in group F (Fig. 2) .
Magnetic resonance imaging (MRI) was used to evaluate the local extent of disease and the possibility of lymph node involvement, and radionuclide bone scans were also per- 
DISCUSSION
An elevated serum PSA level is one of the most important features suggestive of prostate cancer [8, 9] . In most cases, the PSA cutoff of 4 ng/ml is a threshold for performing prostate biopsy. However, the test is painful and invasive, and various complications have been reported in the literature, albeit not common. Most of the complications were minor and did not require hospitalization, but serious life-threatening complications, such as sepsis, also occurred [10] [11] [12] [13] .
In general, the risk of prostate cancer is directly related to the PSA level. Our analysis demonstrated that a serum PSA level higher than 100 ng/ml was 100.0% accurate in predicting the presence of prostate cancer on tissue biopsy. Heyns et al. [14] reported similar results in a large unscreened population. Using a subset of 716 patients with a PSA value higher than 4 ng/ml, they found a positive predictive value of 98% for PSA over 60 ng/ml. Gerstenbluth et al. [4] reported that, when increased to over 50 ng/ml, the serum PSA level was 98.5% accurate in predicting cancer. Thus, they suggested that some highly selected patients may not need to undergo prostate biopsy before androgen deprivation therapy. There may be a disparity between these reports and ours, possibly resulting from racial differences. In our results, the PPV for PSA over 50 ng/ml was merely 81.2%, which was lower than the value in the other Western studies. In other words, the negative predictive value for PSA over 50 ng/ml was higher. It is well known that incidence and disease characteristics vary with race [1, 15] . Also, the number of patients who had PSA over 50 ng/ml was comparatively smaller, resulting in a difference in PPV from other Western studies.
In the study by Egawa et al. [1] , prostate cancer was present in 59.5% of patients with a PSA of 10 ng/ml or higher. Shim et al. [16] also reported that the risk of positive biopsy for PSA levels more than 100 ng/ml was 100%, which was quite similar to our results. Studies of Korean populations have also documented a positive predictive value of 93.8% with a PSA higher than 100 ng/ml and of 94.7% with a PSA higher than 50 ng/ml, which increased to 100.0% in conjunction with an abnormal DRE [17] . In the present study, the detection rate was 100.0% in the subgroup of patients with a PSA of 100 ng/ml or higher.
In group E (PSA, 80 to 100 ng/ml), one patient with a negative biopsy result was followed up for 6 months and a second prostate biopsy was performed, which confirmed prostate cancer. We did not include this patient in group F but rather in group E. This is because this study was conducted to verify the necessity for prostate biopsy in diagnosing prostate cancer; thus, we considered the result of the initial biopsy, not the repeated. Thus, patients with carcinoma reported at their repeated biopsy and not at their initial biopsy were classified as having a negative prostate cancer result. Gerstenbluth et al. [4] have suggested that a negative biopsy in patients with a PSA value of higher than 20 ng/ml is often a false-negative. The likelihood of cancer is significantly increased if the PSA level is persistently high at a subsequent measurement.
The most important role of prostate biopsy is to confirm the diagnosis pathologically, but it also helps to obtain the histologic subtype and to estimate the extent of disease (e.g., the number of positive cores and percentage of positive cores). Therefore, if cancer is expected to be present in almost 100% of a specific patient group, then the value of biopsy is reduced merely to histologic grading and estimation of disease extent [18] .
In our review, all 65 patients in group F (PSA ＞100 ng/ml) had adenocarcinoma. Ninety percent of the patients had a Gleason grade of 4 or higher (i.e., Gleason score of 7 or higher), and radiologic studies showed that all the can- Values are presented as number of patients (%). BMI, body mass index.
cers were stage III or IV (Table 1 ). In addition, the characteristics of the patients in group F are presented in Table  2 . The patient's age, body mass index, Gleason score, and percentage of positive cores was investigated, but the results showed all patients to have high stages. Therefore, the information from the prostate biopsy (e.g., Gleason score and the number of positive cores) does not affect the treatment strategy. If advanced disease is suspected by a super-high PSA level and the results of imaging studies, definitive surgical treatment will not be an option. In our study, all 56 patients received androgen deprivation therapy. Thus, if cancer is suspected in 100% of the patient group, and both disease extent and histologic subtype can be expected to be in a narrow range, undergoing a needle biopsy would be of little value for this specific group (i.e., patients with extremely high levels of serum PSA). Many other prostate diseases affect the PSA level. Inflammation due to infection has been found to produce significant PSA elevation, and up to 6 to 8 weeks might be needed for the PSA value to return to baseline. PSA elevations can also occur as the result of urethral procedures with instrumentation, or following prostatic manipulation, such as the DRE. Therefore, in a patient with an increased PSA level and any recent history of either acute infection, urinary retention, or urinary tract manipulation, prostate biopsy is not mandatory, and a period of time is required to obtain an accurate PSA level [19] [20] [21] . Accordingly, urinary tract infection and urinary retention were exclusion criteria in our study.
The limits of our study are the relatively small number of patients and the retrospective design. To validate this cutoff value, a prospective study is needed to compare patients who underwent prostate biopsy with those who did not.
CONCLUSIONS
Our results suggest the possibility for a biopsy-free diagnosis of prostate cancer, with the criterion of a PSA level ＞100 ng/ml and evidence of advanced disease in imaging studies. We still recommend that any patient who is considered a candidate for surgery or radiation, despite a high PSA level, should undergo biopsy. Nevertheless, because prostate needle biopsy can be associated with several adverse effects, if elderly patients with poor general medical condition present with an extremely elevated serum PSA level, a tissue diagnosis of prostate cancer may not be required for starting androgen deprivation therapy.
